GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data
Vaccine induced strong immune responses in a rat model during preclinical testing
Read More
Tag: CV2CoV
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
